UY37370A - Métodos para tratar esofagitis eosinofílica - Google Patents

Métodos para tratar esofagitis eosinofílica

Info

Publication number
UY37370A
UY37370A UY0001037370A UY37370A UY37370A UY 37370 A UY37370 A UY 37370A UY 0001037370 A UY0001037370 A UY 0001037370A UY 37370 A UY37370 A UY 37370A UY 37370 A UY37370 A UY 37370A
Authority
UY
Uruguay
Prior art keywords
methods
administering
esophagitis
eosinophyl
treat
Prior art date
Application number
UY0001037370A
Other languages
English (en)
Spanish (es)
Inventor
Brian Meltzer
Gail Comer
Original Assignee
Adare Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adare Pharmaceuticals Inc filed Critical Adare Pharmaceuticals Inc
Publication of UY37370A publication Critical patent/UY37370A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Electronic Switches (AREA)
UY0001037370A 2016-08-18 2017-08-18 Métodos para tratar esofagitis eosinofílica UY37370A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376703P 2016-08-18 2016-08-18
US201762461317P 2017-02-21 2017-02-21
US201762489292P 2017-04-24 2017-04-24

Publications (1)

Publication Number Publication Date
UY37370A true UY37370A (es) 2018-01-02

Family

ID=61197039

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037370A UY37370A (es) 2016-08-18 2017-08-18 Métodos para tratar esofagitis eosinofílica

Country Status (11)

Country Link
US (7) US10105315B2 (enExample)
EP (1) EP3500264A4 (enExample)
JP (3) JP6929934B2 (enExample)
KR (3) KR20190039769A (enExample)
AU (2) AU2017312660B2 (enExample)
CA (1) CA3034264A1 (enExample)
NZ (1) NZ750754A (enExample)
RU (1) RU2766577C2 (enExample)
TW (2) TWI777515B (enExample)
UY (1) UY37370A (enExample)
WO (1) WO2018035393A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
KR20150043548A (ko) 2009-10-01 2015-04-22 앱탈리스 파마테크, 인코포레이티드 경구 투여용 코르티코스테로이드 조성물
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
KR102872485B1 (ko) 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
EP3755432A4 (en) * 2018-02-21 2021-12-01 Ellodi Pharmaceuticals, L.P. METHOD OF TREATMENT OF EOSINOPHILIC ESOPHAGITIS
MX2020012064A (es) 2018-05-13 2021-04-13 Regeneron Pharma Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US11672959B2 (en) * 2019-01-18 2023-06-13 Intersect Ent, Inc. Expandable member systems and methods for drug delivery
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
CA3138386A1 (en) 2019-05-02 2020-11-05 Intersect ENT International GmbH Balloon dilation device
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
JP7736667B2 (ja) 2019-08-05 2025-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
US11188680B2 (en) 2019-09-20 2021-11-30 International Business Machines Corporation Creating research study corpus
US11321488B2 (en) 2019-09-20 2022-05-03 International Business Machines Corporation Policy driven data movement
US11328089B2 (en) 2019-09-20 2022-05-10 International Business Machines Corporation Built-in legal framework file management
US11443056B2 (en) 2019-09-20 2022-09-13 International Business Machines Corporation File access restrictions enforcement
US11106813B2 (en) * 2019-09-20 2021-08-31 International Business Machines Corporation Credentials for consent based file access
US11327665B2 (en) 2019-09-20 2022-05-10 International Business Machines Corporation Managing data on volumes
US12691128B2 (en) 2019-10-01 2026-07-28 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and reducing candidiasis
KR20220074915A (ko) * 2019-10-01 2022-06-03 엘로디 파마슈티컬스, 엘.피. 호산구성 식도염을 치료하고 칸디다증을 감소시키는 방법
US11075010B1 (en) * 2020-03-19 2021-07-27 Insight RX, Inc. Pharmacology model optimization based on distributed data acquisition
CA3180487A1 (en) 2020-04-16 2021-10-21 The Medical College Of Wisconsin, Inc. Aerosolized formulations of hiv protease inhibitors for the treatment of airway reflux
US20210330900A1 (en) * 2020-04-22 2021-10-28 Topical Sinus Therapeutics, Inc. TARGETED ADMINISTRATION TO THE OROPHARYNX OF VISCOUS OR DRY POWDER FLUTICASONE PROPIONATE AND RELATED CORTICOSTEROIDS FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EoE)
JP7862322B2 (ja) * 2020-05-22 2026-05-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法
BR112023021510A2 (pt) * 2021-04-20 2024-01-30 Ellodi Pharmaceuticals L P Métodos de tratamento de estenoses esofágicas
CN117715641A (zh) * 2021-04-26 2024-03-15 普拉西斯精密医药公司 用神经活性类固醇进行治疗的方法
EP4091615A1 (en) * 2021-05-20 2022-11-23 Dr. Falk Pharma Gmbh Orodispersible effervescent tablet comprising budesonide for use in the treatment of eosinophilic esophagitis
CA3263472A1 (en) * 2022-07-28 2024-02-01 The Medical College Of Wisconsin, Inc. Extended-release oral formulation of fosamprenavir for the treatment of reflux
WO2025128792A1 (en) * 2023-12-13 2025-06-19 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and depleting mast cell

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1170188A (en) 1967-09-15 1969-11-12 Bayer Ag N-trityl-imidazoles and salts and uses thereof
SE378109B (enExample) 1972-05-19 1975-08-18 Bofors Ab
DE2260384C3 (de) 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US4080448A (en) 1974-11-13 1978-03-21 Mirsky Louis H Method of treating cellular stress
BE887518A (fr) 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
SE8004580L (sv) 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
GB8630913D0 (en) 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
ZA892859B (en) 1988-04-22 1989-12-27 Advanced Polymer Systems Inc Porous particles in preparations involving immiscible phases
GB9002375D0 (en) 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
US5278175A (en) 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
CA2101773A1 (en) 1991-01-31 1992-08-01 Toyoichi Tanaka Interpenetrating-polymer network phase-transition gels
EP0735884B1 (en) 1993-12-20 2000-04-26 Minnesota Mining And Manufacturing Company Flunisolide aerosol formulations
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5863910A (en) * 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
DE19606151C2 (de) 1996-02-20 1999-05-12 Losan Pharma Gmbh Ibuprofen-Brausezubereitung sowie Verfahren zur Herstellung derselben
PT914818E (pt) 1996-06-14 2005-08-31 Kyowa Hakko Kogyo Kk Comprimido de desintegracao rapida por via intraoral
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
SE9604486D0 (sv) 1996-12-05 1996-12-05 Astra Ab Novel formulation
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
RO118174B1 (ro) 1997-08-21 2003-03-28 Aventis Pharma Deutschland Gmbh Lac de unghii şi utilizarea acestuia
EP1058538B9 (en) 1998-03-06 2013-01-02 Aptalis Pharma S.r.l. Fast disintegrating tablets
FR2781156B1 (fr) 1998-07-20 2001-06-29 Lafon Labor Composition pharmaceutique destinee notamment a la prevention et au traitement des radiomucites et des chimiomucites
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
CN1173703C (zh) 1999-04-23 2004-11-03 里奥药物制品有限公司 药物组合物
IT1317904B1 (it) 1999-09-11 2003-07-15 Glaxo Group Ltd Formulazione farmaceutica di propionato di fluticasone.
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US20030050312A1 (en) 2001-03-12 2003-03-13 Hjorth Thyge Borup Novel tablets and capsules and a process for its preparation
EP1418945A2 (en) 2001-03-13 2004-05-19 Angiotech Pharmaceuticals, Inc. Micellar drug delivery vehicles and uses thereof
KR100642976B1 (ko) 2001-05-10 2006-11-10 아스텔라스세이야쿠 가부시키가이샤 구강내 신속 붕괴성 정제 및 이의 제조방법
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
US6656493B2 (en) 2001-07-30 2003-12-02 Wm. Wrigley Jr. Company Edible film formulations containing maltodextrin
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
JP4173670B2 (ja) 2002-03-08 2008-10-29 旭化成ファーマ株式会社 口腔内崩壊製剤
MXPA04010778A (es) 2002-05-03 2005-03-07 Janssen Pharmaceutica Nv Microemulsiones polimericas.
AU2003270357A1 (en) 2002-09-06 2004-03-29 Microbia, Inc. Inhibitors of fungal invasion
AU2003272450A1 (en) 2002-09-13 2004-04-30 C. Steven Smith Novel composition and method for treatment of upper respiratory conditions
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2004064810A1 (ja) 2003-01-21 2004-08-05 Nippon Shinyaku Co., Ltd. 口腔内速崩性錠剤
SI1587514T1 (sl) 2003-01-31 2006-10-31 Orexo Ab Hitro ucinkujoc farmacevtski sestavek
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20050009848A1 (en) 2003-07-10 2005-01-13 Icn Pharmaceuticals Switzerland Ltd. Use of antivirals against inflammatory bowel diseases
US20060134054A1 (en) 2003-12-19 2006-06-22 Council Of Scientific And Industrial Research Polymer composition for pH dependent dissolution behavior and process for preparation thereof
DE602005014227D1 (de) 2004-03-10 2009-06-10 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
ATE353635T1 (de) 2004-09-09 2007-03-15 Medinfar Produtos Farmaceutico Schnell wasserdispergierbare und domperidon enthaltende tabletten
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
TW200800142A (en) 2005-09-09 2008-01-01 Univ Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) * 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2007158225A (ja) 2005-12-08 2007-06-21 Canon Inc 露光装置
CN1985799B (zh) 2005-12-19 2011-11-09 量子高科（北京）研究院有限公司 口腔崩解制剂的制备方法
WO2007074472A2 (en) 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
EP1958613A1 (en) 2007-02-15 2008-08-20 Polichem S.A. Dermal film-forming liquid formulations for drug release to skin
CA2721133C (en) 2007-04-13 2018-11-06 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations and methods of making and using the same
US20090123551A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
DK3354276T3 (da) * 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
US20150231156A1 (en) * 2007-11-13 2015-08-20 Meritage Pharma, Inc. Corticosteroid compositions
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
BRPI0820997A2 (pt) 2007-12-10 2014-12-23 Eurand Inc Comprimidos de desintegração oral compreendendo difenidramina.
BRPI0821761A2 (pt) 2007-12-21 2015-06-16 Eurand Inc Composições de comprimidos de desintegração oral de temazepam
JP2009173552A (ja) 2008-01-21 2009-08-06 Lion Corp 胃腸薬
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
SI2151235T1 (sl) 2008-07-21 2011-04-29 Falk Pharma Gmbh Farmacevtska formulacija za zdravljenje zgornjega prebavnega trakta
EP2328558A2 (en) 2008-08-08 2011-06-08 McNeil-PPC, Inc. Use of sucralose as a granulating agent
EP2328553B1 (en) 2008-08-20 2020-06-10 The Regents of The University of California Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
MX2011007578A (es) 2009-01-15 2011-08-04 Nestec Sa Metodos para diagnosticar y tratar la disfagia.
JP2012518655A (ja) 2009-02-23 2012-08-16 アプタリス ファーマテック インコーポレイテッド プロトンポンプ阻害剤を含む制御放出組成物
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
CN102596237A (zh) 2009-09-07 2012-07-18 Dbv技术公司 治疗嗜酸细胞性食管炎的方法
KR20150043548A (ko) 2009-10-01 2015-04-22 앱탈리스 파마테크, 인코포레이티드 경구 투여용 코르티코스테로이드 조성물
MX337603B (es) 2009-11-30 2016-03-10 Adare Pharmaceuticals Inc Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion.
US20120164080A1 (en) * 2010-06-24 2012-06-28 Meritage Pharma, Inc. Methods of treatment for esophageal inflammation
NZ611467A (en) 2010-12-02 2015-06-26 Aptalis Pharmatech Inc Rapidly dispersing granules, orally disintegrating tablets and methods
AU2012208912B2 (en) 2011-01-18 2016-03-03 Holland Bloorview Kids Rehabilitation Hospital Method and device for swallowing impairment detection
DK2667777T3 (en) 2011-01-28 2016-10-03 Nestec Sa APPARATUS FOR DIAGNOSIS OF SAG dysfunction
CN104114169A (zh) 2011-12-16 2014-10-22 阿托佩斯治疗有限公司 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
US20150209432A1 (en) 2012-07-26 2015-07-30 Lupin Limited Pharmaceutical compositions of proton pump inhibitor
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
LT2886108T (lt) * 2013-12-23 2019-03-25 Dr. Falk Pharma Gmbh Optimizuota farmacinė kompozicija, skirta stemplės uždegiminių pakitimų gydymui
WO2015142739A1 (en) 2014-03-17 2015-09-24 Children's Hospital Medical Center Genetic test for determining susceptibility for eosinophilic esophagitis
US10176301B2 (en) 2014-09-11 2019-01-08 Meritage Pharma, Inc. Systems, methods, and software for providing a patient-reported outcome measure of dysphagia patients with eosinophilic esophagitis
US9980975B2 (en) * 2015-01-22 2018-05-29 Ems S.A. Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus
US10869592B2 (en) 2015-02-23 2020-12-22 Uroviu Corp. Handheld surgical endoscope
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
EP3755432A4 (en) 2018-02-21 2021-12-01 Ellodi Pharmaceuticals, L.P. METHOD OF TREATMENT OF EOSINOPHILIC ESOPHAGITIS
US12691128B2 (en) 2019-10-01 2026-07-28 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and reducing candidiasis
KR20220074915A (ko) 2019-10-01 2022-06-03 엘로디 파마슈티컬스, 엘.피. 호산구성 식도염을 치료하고 칸디다증을 감소시키는 방법
WO2022020464A1 (en) 2020-07-21 2022-01-27 Ellodi Pharmaceuticals, L.P. Modified release rapidly disintegrating compositions of proton pump inhibitors
BR112023021510A2 (pt) 2021-04-20 2024-01-30 Ellodi Pharmaceuticals L P Métodos de tratamento de estenoses esofágicas

Also Published As

Publication number Publication date
US12059494B2 (en) 2024-08-13
JP6929934B2 (ja) 2021-09-01
TWI777515B (zh) 2022-09-11
AU2017312660A1 (en) 2019-03-07
KR20210095973A (ko) 2021-08-03
TW202206079A (zh) 2022-02-16
AU2017312660B2 (en) 2023-06-29
US11896710B2 (en) 2024-02-13
TWI728172B (zh) 2021-05-21
US10105315B2 (en) 2018-10-23
JP2019528272A (ja) 2019-10-10
KR20190039769A (ko) 2019-04-15
CA3034264A1 (en) 2018-02-22
US20200368147A1 (en) 2020-11-26
JP2024164004A (ja) 2024-11-26
TW201808304A (zh) 2018-03-16
US20250170057A1 (en) 2025-05-29
US20190008760A1 (en) 2019-01-10
EP3500264A1 (en) 2019-06-26
EP3500264A4 (en) 2020-04-29
US11684571B2 (en) 2023-06-27
US20210275438A1 (en) 2021-09-09
KR20230167146A (ko) 2023-12-07
NZ750754A (en) 2023-02-24
AU2023233115A1 (en) 2023-10-12
JP2021178866A (ja) 2021-11-18
RU2766577C2 (ru) 2022-03-15
US20180133145A1 (en) 2018-05-17
RU2019105805A3 (enExample) 2020-11-13
US11026887B2 (en) 2021-06-08
US20230414498A1 (en) 2023-12-28
JP7526143B2 (ja) 2024-07-31
RU2019105805A (ru) 2020-09-18
WO2018035393A1 (en) 2018-02-22
US20210346278A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
NZ750754A (en) Methods of treating eosinophilic esophagitis
MX2021013788A (es) Dosificación del inhibidor de kras para el tratamiento de cánceres.
CL2021000622A1 (es) Uso de niclosamida para la preparación de un medicamento para el tratamiento de colitis autoinmune, una enfermedad inflamatoria intestinal, colitis autoinmune iatrogénica, divisional de la solicitud de patente nº 559-2018.
CL2017001117A1 (es) Métodos para tratar enfermedades oculares.
MX2017011375A (es) Método para tratar un tumor cerebral.
MX2019006864A (es) Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de factor de necrosis tumoral (tnf).
MX363000B (es) Composiciones y usos de las mismas para tratar la inflamación.
MX2016016800A (es) Metodos para el tratamiento del sobrepeso o la obesidad.
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
CR20140086A (es) Tratamientos de combinación para hepatitis c
ECSP15008695A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
PH12017500747B1 (en) Heterocyclic compound
MX2016015436A (es) Compuestos para tratar el cancer cerebral.
MX2017004558A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
DOP2012000174A (es) Metodo de tratamiento
DOP2023000155A (es) Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina
MX2017015926A (es) Uso de derivados de bencimidazol para escape acido nocturno.
MX2015011671A (es) Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2021014524A (es) Metodos para tratar canceres del sistema urinario.
MX2016015695A (es) Metodos para tratar y prevenir enfermedades de inestabilidad vascular.
TW201613639A (en) Methods for treating cardiovascular diseases
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
AR102308A1 (es) Composición farmacéutica para usar en el tratamiento o prevención de deficiencias de vitaminas y minerales en pacientes sometidos a cirugía de bypass gástrico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230626